HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Review Reorganization Boosts Advisory Role Of Medical Imaging Division

Executive Summary

FDA's reorganization of its drug review divisions will allow the Office of New Drugs' medical imaging staff to assume a broader role in consulting on trials that use medical images as an endpoint
Advertisement

Related Content

Oncology Drug Reviews To Be Restructured As Office Shifts Away From Divisions Organized Around Molecule Size
Oncology Drug Reviews To Be Restructured As Office Shifts Away From Divisions Organized Around Molecule Size
Oncology Drug Reviews To Be Restructured As Office Shifts Away From Divisions Organized Around Molecule Size
FDA, Imaging Industry Hear Advice On Radiation Safety Improvements
Office Of New Drugs Reorganization Should Better Balance Workload, FDA Says
FDA Develops Separate Set Of GMP Requirements For PET Drug Makers

Topics

Advertisement
UsernamePublicRestriction

Register

PS052111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel